Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...
Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
Novo Nordisk launches NovoCare rivaling Eli Lilly’s LillyDirect
Rivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk ...
ZAWYA1h
African drugmaker Aspen says new Latam and Eli Lilly portfolio boosting earnings
Normalised earnings before interest, tax, depreciation and amortisation (EBITDA) from commercial pharmaceuticals grew 13% ...
WAMC Northeast Public Radio19h
Consumers can buy Zepbound and Wegovy direct from drugmakers if they pay cash
Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...
Fierce Pharma22h
Lilly’s 1st DTC Ebglyss campaign highlights eczema’s effects on a range of skin tones and age groups
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...
Indianapolis Business Journal17h
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly
Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...
The Lever2h
You’ve Already Paid $6 Billion For Weight-Loss Drugs You Can’t Afford
U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could ...